Efficacy, Safety and Tolerability of Zolpidem in the Treatment of Children Aged 6 to 17 Years With ADHD-Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study.

Trial Profile

Efficacy, Safety and Tolerability of Zolpidem in the Treatment of Children Aged 6 to 17 Years With ADHD-Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Zolpidem (Primary)
  • Indications Attention-deficit hyperactivity disorder; Insomnia
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 09 Dec 2008 Actual end date and patient number reported by Clinicaltrials.gov.
    • 13 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top